Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
Immunovant (IMVT) Gets a Buy From Piper Sandler
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
Don't Ignore The Insider Selling In Immunovant
We wouldn't blame Immunovant, Inc. (NASDAQ:IMVT) shareholders if they were a little worried about the fact that Peter Salzmann, the CEO & Director recently netted about US$990k selling shares at an av
Buy Rating Affirmed for Immunovant on Strong Drug Development Prospects and Efficacy Confidence
Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing
Peter Salzmann, Director, Chief Executive Officer, on April 17, 2024, sold 34,079 shares in Immunovant (IMVT) for $990,269. Following the Form 4 filing with the SEC, Salzmann has control over a total
What Makes Immunovant (IMVT) a New Buy Stock
Immunovant Initiated at Outperform by Oppenheimer
Immunovant Initiated at Outperform by Oppenheimer
Oppenheimer Initiates Coverage On Immunovant With Outperform Rating, Announces Price Target of $50
Oppenheimer analyst Leland Gershell initiates coverage on Immunovant with a Outperform rating and announces Price Target of $50.
Truist Securities Reiterates Buy on Immunovant, Maintains $48 Price Target
Truist Securities analyst Robyn Karnauskas reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $48 price target.
Buy Rating for Immunovant Amidst Strong Market Position and Promising Batoclimab Trials
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersYield10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The market value of their outstanding shares is at $6.8 million. Immunovant (NASDAQ:IMV
11 Oversold Biotech Stocks To Buy Right Now
Immunovant Initiated at Buy by Goldman Sachs
Immunovant Initiated at Buy by Goldman Sachs
Goldman Sachs Initiates Coverage On Immunovant With Buy Rating, Announces Price Target of $50
Goldman Sachs analyst Corinne Johnson initiates coverage on Immunovant (NASDAQ:IMVT) with a Buy rating and announces Price Target of $50.
Immunovant Inc.: A Strong Buy on IMVT-1402's Market Potential and Upcoming Clinical Catalysts
Immunovant Awarded U.S. Patent for IMVT-1402
Composition of matter patent issued with coverage until June 2043Patent also includes methods of use and methods of manufacturing claims NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Immunovant (NASDAQ:IMVT) shareholders have done very well over the last year, with the share price s
Wells Fargo Screens for Momentum Names to Play and Contrarian Plays to Avoid
Immunovant Inc CFO Eva Barnett Sells 2,930 Shares
No Data